ClinicalTrials.gg
RecruitingNCT07338526IMPORTUpdated Jan 30, 2026

Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT)

An interventional study of Intensity-modulated proton therapy (IMPT) and Photon-based intensity-modulated radiation therapy (IMRT). in Brain Tumor, Pediatric, sponsored by Tata Memorial Centre. Recruiting at 1 site in India. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Tata Memorial Centre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2025, registered Nov 2025).
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
6 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Brain Neoplasms with a site in India — 9 open to participants now, 10 under way, 3 of them phase 3. Brain Neoplasms · India.

Planned enrollment
9th of 11
94 · median 156
Started
2025
with 3 others
No phase
2 of 24
2 open now
Registered
19th of 24
by date
Lead sponsor
7 of 24
Tata Memorial Centre

Among the 24 studies in Brain Neoplasms with a site in India, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2025, is one of 2 with no phase, and was the 19th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

9 of the 24 studies in Brain Neoplasms with a site in India are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 6 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Brain Neoplasms with a site in India, or all of them as a file.
02

Study summary

Children diagnosed with benign or low-grade brain tumors often require radiation therapy to control their disease. While radiation can be effective, traditional techniques using X-rays (photon-based radiotherapy) expose healthy brain tissue to radiation, potentially leading to long-term side effects like memory loss, learning difficulties, hormone imbalances, hearing problems, and a higher risk of secondary cancers. This study, called the IMPORT Trial, aims to compare two types of radiation therapy-Intensity-Modulated Proton Therapy (IMPT) and Intensity-Modulated Radiation Therapy (IMRT)-to determine which is safer and more effective for children. IMPT, a newer technique, uses protons instead of X-rays to deliver radiation, reducing exposure to healthy brain tissue. Researchers believe this could help minimize long-term damage while maintaining effective tumor control.

What is the goal of the study?

The primary goal is to see if IMPT leads to better survival with fewer side effects compared to IMRT. The study will track how well children function over five years, looking at:

  • Cognitive abilities (memory, attention, learning)
  • Hormonal balance (pituitary gland function)
  • Hearing ability
  • Overall survival without significant decline in quality of life

How will the study work?

  • Who can join? Children aged 6 to 16 years diagnosed with certain types of benign or low-grade brain tumors.
  • How are patients treated? Patients will be randomly assigned to receive either IMRT or IMPT.
  • What is analysed? Doctors will track survival, tumor control, cognitive function, endocrine health, and quality of life over time.
  • How long will it take? The study will last 10 years (5 years to enroll patients, 5 years to follow up).

Proton therapy is more expensive and not widely available, so strong scientific evidence is needed to justify its use in routine treatment. If IMPT significantly improves quality of life and survival, it could become the preferred treatment, shaping future policies and making proton therapy more accessible for children who need it.

Read the detailed description

Benign and low-grade primary brain tumors constitute a substantial proportion of pediatric central nervous system tumors and are associated with excellent long-term survival when managed with multimodality therapy. Despite favorable tumor control rates, survivors are at significant risk of treatment-related late effects, particularly following radiation therapy, which can adversely impact neurocognitive function, endocrine health, auditory function, and overall quality of life. Given the prolonged life expectancy of this population, minimizing radiation-induced toxicity while maintaining effective disease control is a major therapeutic priority.

Radiation therapy remains an essential curative modality for children with unresectable, residual, progressive, or recurrent benign and low-grade brain tumors. Advances in high-precision photon-based techniques such as intensity-modulated radiation therapy (IMRT) have improved dose conformality; however, photon therapy continues to expose large volumes of normal brain tissue to low and intermediate radiation doses. This exposure may lead to white matter injury, neuroinflammation, microvascular damage, and subsequent neurocognitive, endocrine, and auditory dysfunction, particularly in younger patients with developing brains.

Proton beam therapy offers a potential dosimetric advantage over photon therapy due to its physical depth-dose characteristics, allowing reduced integral dose to surrounding normal tissues. Intensity-modulated proton therapy (IMPT), delivered using pencil beam scanning, enables highly conformal dose distributions with improved sparing of organs at risk and may allow for reduction in treatment margins through enhanced image guidance and dose painting capabilities. These properties suggest a potential for meaningful reduction in late radiation-related toxicity in pediatric patients, while preserving tumor control.

While dosimetric and retrospective clinical data suggest advantages of proton therapy in reducing radiation exposure to critical neural structures, robust prospective randomized evidence demonstrating clinically meaningful benefits remains limited. Furthermore, the higher cost and limited availability of proton therapy necessitate careful evaluation of its value relative to advanced photon techniques, particularly in resource-constrained healthcare systems. Generating high-level evidence to guide patient selection and policy decisions is therefore essential.

The IMPORT trial is a prospective, randomized, open-label, phase III superiority study designed to compare IMPT with IMRT in children with benign and low-grade primary brain tumors treated with curative intent radiotherapy. The trial focuses on outcomes that are particularly relevant to long-term pediatric survivorship, including neurocognitive function, endocrine and auditory toxicity, and quality of life, while ensuring comparable tumor control.

The study introduces the concept of Qualified Overall Survival (qOS) as a composite primary endpoint that integrates survival, disease control, and clinically significant treatment-related morbidity. This composite endpoint is intended to capture outcomes that reflect both oncologic efficacy and functional preservation, thereby providing a patient-centered assessment of treatment benefit.

Participants will be randomized to receive either IMPT or IMRT, with radiation dose, fractionation, and target volumes determined by tumor type, location, and standard clinical practice. Tumor response and disease progression will be assessed using contemporary imaging-based criteria, while functional outcomes will be evaluated using standardized neurocognitive testing, endocrine assessments, audiological evaluations, and patient-reported quality-of-life instruments.

By directly comparing IMPT and IMRT in a randomized setting, the IMPORT trial aims to determine whether the dosimetric advantages of proton therapy translate into superior long-term functional outcomes and improved qualified survival, thereby informing evidence-based clinical decision-making and health policy for pediatric brain tumor management.

03

Conditions studied

  • Brain Tumor, Pediatric

Browse trials for

Keywords

  • Brain tumor, Benign
  • Brain tumor, Pediatric
04

Who can participate

Ages eligible
6 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age at irradiation: 6 to 16 years
  • / Lansky Play Performance Status ≥ 60
  • Diagnosis (histopathological/ radiological) of primary brain tumor with an expected survival of >5 years (e.g., circumscribed gliomas, low grade gliomas, low-grade glial/ glioneuronal tumors, meningioma, pituitary tumors, schwannoma, craniopharyngioma, ependymoma)
  • Planned for focal cranial radiotherapy
  • taken

Exclusion criteria

Exclusion Criteria:

  • Re-irradiation
  • Palliative radiotherapy
  • Multifocal or multicentric disease
  • Planned for whole brain irradiation or craniospinal irradiation
  • Planned for hypo-fractionated or stereotactic radiotherapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
94 participants (estimated)

Study arms

  • Other
    Control Arm

    Patients in the standard arm will undergo focal cranial radiotherapy using photons (X-rays) with Image Guided Intensity Modulated Radiotherapy(IG-IMRT) using Volumetric Modulated Arc Therapy(VMAT).

    Radiation: Photon-based intensity-modulated radiation therapy (IMRT).

  • Experimental
    Experimental Arm

    The patients in the experimental arm will undergo focal radiotherapy to an equivalent dose using protons with pencil beam scanning- IMPT or volumetric modulated proton arc therapy.

    Radiation: Intensity-modulated proton therapy (IMPT)

Interventions

  • RadiationIntensity-modulated proton therapy (IMPT)

    Patients in the experimental arm will receive focal cranial radiotherapy using proton therapy delivered with IMPT or proton arc techniques. Dose prescriptions and volumes will match institutional standards independent of study allocation. Planning will include CT and MRI fusion, with target and OAR delineation identical to the control arm. Proton plans will use robust optimization and undergo multidisciplinary review. Treatment will be delivered with image guidance, with weekly toxicity monitoring and standard clinical and imaging follow-up.

  • RadiationPhoton-based intensity-modulated radiation therapy (IMRT).

    Patients in the control arm will receive focal cranial radiotherapy using photon-based IG-IMRT delivered with VMAT. Dose, fractionation, and target volumes will follow standard institutional protocols based on tumor type and molecular features. Planning CT and MRI fusion will guide contouring of GTV, CTV, PTV, and organs at risk. Treatment plans will be generated in the Treatment Planning System and reviewed in multidisciplinary meetings. Radiotherapy will be delivered on IGRT-equipped linear accelerators, with weekly assessments for acute toxicities and routine follow-up imaging as per standard care.

06

What researchers measure

Primary outcomes

  1. Survival Outcome

    Qualified Overall Survival (qOS) is a composite endpoint defined as survival without functional, cognitive, or quality-of-life deterioration, irrespective of whether the cause is disease progression or treatment toxicity. The study hypothesizes that IMPT is superior to IMRT for 5-year qOS. qOS is measured from randomization to the earliest of: 1. death from any cause; 2. radiological progression confirmed on multiparametric MRI with two scans ≥12 weeks apart or deemed progressive by multidisciplinary consensus; 3. neurocognitive decline \>10 IQ points on Wechsler scales; 4. clinically significant hypopituitarism requiring hormonal supplementation (CTCAE v5 Grade ≥2); 5. Grade ≥2 ototoxicity; or 6. symptomatic radiation necrosis requiring corticosteroids \>4 weeks or anti-angiogenic therapy (e.g., bevacizumab).

    Time frame: 5 years

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (defined as the time elapsed between date of randomisation to death due to any cause)

    Time frame: At 5 years

  2. Progression-free Survival (PFS)

    Progression-free survival(defined as the time elapsed between date of randomisation to documented clinico-radiological progression or death)

    Time frame: at 5 years

  3. Quality of Life indices

    Quality of life assessed using patient-reported outcome measures developed by the European Organisation for Research and Treatment of Cancer (EORTC), including the core and disease-specific modules administered in this study. Scores are linearly transformed to a range of 0 to 100. For functional scales and global health status, higher scores indicate better quality of life; for symptom scales, higher scores indicate worse symptoms. Assessed at baseline and follow-up. Unit of Measure: Units on a scale

    Time frame: Pre-Radiotherapy (Baseline), Radiotherapy conclusion- within 1 week, 3-months post RT, 1-year post RT, annually till 5-years

  4. Cost-effectiveness based on EQ-5D-5L derived utilities

    Health-related quality of life for economic evaluation will be assessed using the EuroQol 5-Level 5-Dimension questionnaire (EQ-5D-5L). Responses will be converted to utility scores using a country-specific value set and used to estimate quality-adjusted life years (QALYs) for cost-effectiveness analysis. Assessed at baseline and follow-up. Unit of Measure: Quality-adjusted life years (QALYs)

    Time frame: Pre-Radiotherapy (Baseline), Radiotherapy conclusion- within 1 week, 3-months post RT, 1-year post RT, annually till 5-years

  5. Response Rate (RR)

    Response Rate (complete and partial response) as decided by contemporary image-based response criteria (RAPNO, RANO-LGG 2.0)

    Time frame: Radiotherapy conclusion- within 1 week, 3-months post RT, 1-year post RT, annually till 5-years

  6. Sub-domain of qOS

    Cumulative incidence of sub-domains of qualified overall survival

    Time frame: Radiotherapy conclusion- within 1 week, 3-months post RT, 1-year post RT, annually till 5-years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2035, 119 months after the start.

Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 119 months is above that.

Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Jan 14, 2026
StartActual
Aug 7, 2025
Primary completionEst.
Jul 7, 2035
CompletionEst.
Jul 7, 2035
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07338526
Lead sponsor
Tata Memorial Centre
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Aug 7, 2025
Primary completion
Jul 7, 2035 (estimated)
Completion
Jul 7, 2035 (estimated)
Last update
Jan 30, 2026

Study contacts

Abhishek Chatterjee, MD
Contact
chatterji08@gmail.com
2224177000 ext. 6015

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion